文献速递细菌感染、耐药与抗菌药物

实验室自建抗菌药物敏感性试验新监管将如何影响感染病临床实践

How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice.
PubMed 文献 · Clin Infect Dis · 2024-01-01

美国食品药品监督管理局(FDA)提议监管实验室自建检测(LDT),而FDA折点列表相对较短,许多药物-细菌组合缺乏FDA折点,可能导致关键临床适应证的AST丧失并抑制技术创新。有效解决方案需要制造商、感染病临床医生、药师、实验室和FDA协作。

要点

  • FDA提议监管LDT,且FDA折点列表相对较短,许多药物-细菌组合无FDA折点。
  • 风险包括关键临床适应证的AST丧失和技术创新受抑制,需多方协作解决。

核心结论

  • FDA提议监管LDT,加之许多药物-细菌组合缺乏FDA折点,可能导致关键临床适应证的AST丧失并抑制技术创新。
  • 有效解决方案需要制造商、感染病临床医生、药师、实验室和FDA协作。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 当前和拟议的FDA监管政策危及许多微生物AST的未来可用性。
  • 进行AST的设备必须使用FDA的敏感性试验解释标准(即折点)获得许可。
  • FDA折点列表相对较短,实验室目前使用临床和实验室标准协会发布的折点、遗留设备和LDT来补充FDA折点。

关键数值与推荐

  • 原文未报告具体标准与数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance (AMR) affects 2.8 million Americans annually. AMR is identified through antimicrobial susceptibility testing (AST), but current and proposed regulatory policies from the United States Food and Drug Administration (FDA) jeopardize the future availability of AST for many microorganisms. Devices that perform AST must be cleared by the FDA using their susceptibility test interpretive criteria, also known as breakpoints. The FDA list of breakpoints is relatively short. Today, laboratories supplement FDA breakpoints using breakpoints published by the Clinical and Laboratory Standards Institute, using legacy devices and laboratory-developed tests (LDTs). FDA proposes to regulate LDTs, and with no FDA breakpoints for many drug-bug combinations, the risk is loss of AST for key clinical indications and stifling innovation in technology development. Effective solutions require collaboration between manufacturers, infectious diseases clinicians, pharmacists, laboratories, and the FDA.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wolfe KH, Pierce VM, Humphries RM, et al. How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice. Clin Infect Dis. 2024. PMID: 38573057. doi:10.1093/cid/ciae075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。